JDD April 2024 Issue Highlights
215362153621536
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen …
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen … 
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Dr. Friedman, jack of many trades, Professor and Interim Chair of Dermatology at George Washington University provided an excellent overview of ways to achieve victory over atopic dermatitis (AD). This expert discussion took place during the ODAC Inflammatory Diseases Symposium on December 3, 2020.
How could we possibly cover atopic dermatitis in 20 minutes? Well, Dr. Friedman skillfully led us … 